| Literature DB >> 33213442 |
Bruno Leitão-Almeida1, Octavi Camps-Font2, André Correia3, Javier Mir-Mari2, Rui Figueiredo2, Eduard Valmaseda-Castellón2.
Abstract
BACKGROUND: Peri-implantitis is a biological complication that affects soft and hard tissues around dental implants. Implantoplasty (IP) polishes the exposed implant surface, to decontaminate it and make it less prone to bacterial colonization. This study investigates whether a higher clinical crown-to-implant-ratio (CIR) reduces implant fracture resistance and whether implants are more fracture-prone after IP in the presence of 50% of bone loss.Entities:
Keywords: Compressive strength; Dental implants; Implantoplasty; Peri-implantitis; Titanium
Year: 2020 PMID: 33213442 PMCID: PMC7678153 DOI: 10.1186/s12903-020-01323-z
Source DB: PubMed Journal: BMC Oral Health ISSN: 1472-6831 Impact factor: 2.757
Fig. 1a Study design, groups and subgroups; b sample before IP; c sample after IP
Fig. 2Radiographic measurements of the implant wall width. Left: control implant; right: IP implant. Blue lines: length at middle of the first (R1) and tenth (R2) threads and at the end of the prosthetic screw hole (R3), perpendicularly to the long axis of the implant; red line: 1.9 mm reference
Fig. 3IP samples after fracture test: a CIR 2:1, b CIR 2.5:1, c CIR 3:1, d fracture test diagram
Implant wall width measurements (mm) of IP and control samples at each reference point (n = 48)
| Reference point | Control | IP | |||
|---|---|---|---|---|---|
| Mean (SD) | Mean (SD) | MD (95%CI) | Independent samples | ANOVA | |
| R1 (first thread) | |||||
| 2:1 | 3.44 (0.02) | 3.03 (0.04) | 0.41 (0.37–0.44) | < 0.001* | 0.103 |
| 2.5:1 | 3.44 (0.01) | 3.03 (0.04) | 0.41 (0.38–0.45) | < 0.001* | |
| 3:1 | 3.45 (0.02) | 3.08 (0.04) | 0.37 (0.33–0.40) | < 0.001* | |
| R2 (tenth thread) | |||||
| 2:1 | 3.32 (0.03) | 2.86 (0.03) | 0.46 (0.42–0.49) | < 0.001* | 0.949 |
| 2.5:1 | 3.31 (0.02) | 2.86 (0.04) | 0.45 (0.41–0.49) | < 0.001* | |
| 3:1 | 3.34 (0.03) | 2.89 (0.06) | 0.46 (0.41–0.50) | < 0.001* | |
| R3 (end of the prosthetic screw hole) | |||||
| 2:1 | 3.07 (0.03) | 2.62 (0.06) | 0.45 (0.40–0.50) | < 0.001* | 0.163 |
| 2.5:1 | 3.07 (0.05) | 2.64 (0.04) | 0.43 (0.38–0.47) | < 0.001* | |
| 3:1 | 3.07 (0.02) | 2.68 (0.04) | 0.40 (0.36–0.43) | < 0.001* | |
*Statistically significant difference
MD mean difference (Control—IP)
Mean fracture strength (N) of the three CIR in the IP and control samples
| CIR | Control | IP | ||
|---|---|---|---|---|
| Mean (SD) | Mean (SD) | MD (95%CI) | Adjusted | |
| 2:1 | 1276.16 (169.75) | 1211.70 (281.64) | 64.46 (− 117.17 to 246.09) | 0.478 |
| 2.5:1 | 815.22 (185.58) | 621.68 (186.28) | 193.54 (11.91–375.17) | 0.037* |
| 3:1 | 606.55 (111.48) | 465.95 (68.57) | 140.60 (− 41.03 to 322.24) | 0.126 |
| Total | 899.31 (323.58) | 766.44 (379.19) | 132.87 (− 71.95 to 337.69) | 0.198 |
*Statistically significant difference
MD mean difference (Control—IP)
Fig. 4Mean fracture strength (N) of the three CIR ratios in the IP and control samples
Mean fracture strength (N) of the IP and control groups in the three clinical CIR subgroups
| Group | CIR1 | CIR2 | MD (95% CI) | Adjusted |
|---|---|---|---|---|
| Control | 2:1 | 2.5:1 | 460.94 (242.27–679.60) | < .001* |
| 3:1 | 669.60 (450.94–888.27) | < .001* | ||
| 2.5:1 | 3:1 | 208.67 (− 9.99 to 427.33) | .064 | |
| IP | 2:1 | 2.5:1 | 590.02 (371.36–808.68) | < .001* |
| 3:1 | 745.75 (527.09–964.41) | < .001* | ||
| 2.5:1 | 3:1 | 155.73 (− 62.93 to 374.39) | .206 | |
| Total | 2:1 | 2.5:1 | 525.48 (363.58–687.38) | < .001* |
| 3:1 | 707.68 (545.78–869.57) | < .001* | ||
| 2.5:1 | 3:1 | 182.20 (20.30–344.10) | < .001* |
*Statistically significant difference
MD mean difference (CIR1—CIR2)
Fig. 5SEM screening: a IP sample platform fracture; b control sample platform fracture; c IP sample body fracture; d prosthetic screw fracture;